Last 12 months
Inside the activity.
0 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2019 Filed Feb 16, 2019 00:48 UTC |
Kuipers Peter J.Executive V P& CFO
|
GrantStock Option (Right to Buy) · Derivative | 28,708 | $0.00 Strike: $78.91 | $0.00 |
DisclosureSEC source: 0001179110-19-002027 · edgar.xml · derivative · entry 4 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,708 Underlying: Common Stock · 28,708 shares Expires 2029-02-12 F2 · shares: Shares shall vest ratably over 48 month period, with a year cliff. Read SEC document |
| February 13, 2019 Filed Feb 16, 2019 00:48 UTC |
Kuipers Peter J.Executive V P& CFO
|
GrantCommon Stock | 6,843 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002027 · edgar.xml · nonDerivative · entry 3 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,093 F1 · shares: Restricted Stock Units shall vest semiannually on 6/15 and 12/15 for a period of 4 years. Read SEC document |
| February 13, 2019 Filed Feb 16, 2019 00:48 UTC |
Kuipers Peter J.Executive V P& CFO
|
GrantCommon Stock | 7,865 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002027 · edgar.xml · nonDerivative · entry 2 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,250 F3 · shares: The Performance-based restricted stock unit awards vest as to 25% of the shares on the date of the Compensation Committee meeting in 2020 when the Committee reviews the performance-based metrics and determines if they were met or not with the remaining shares vesting on a semi-annual basis over a period of thirty-six months commencing on June 15, 2020 if the Company meets certain stock performance objectives compared to the NASDAQ Healthcare Index. The actual number of performance based stock awards that vest may be 0%, 50% or 100% of the numbers reflected above, depending upon the Company's performance. Read SEC document |
| February 13, 2019 Filed Feb 16, 2019 00:49 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 83,845 | $0.00 Strike: $78.91 | $0.00 |
DisclosureSEC source: 0001179110-19-002029 · edgar.xml · derivative · entry 5 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,845 Underlying: Common Stock · 83,845 shares Expires 2029-02-12 F3 · shares: Shares shall vest ratably over 48 month period, with a year cliff. Read SEC document |
| February 13, 2019 Filed Feb 16, 2019 00:49 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
GrantCommon Stock | 39,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002029 · edgar.xml · nonDerivative · entry 4 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,793 F4 · shares: The Performance-based restricted stock unit awards vest as to 25% of the shares on the date of the Compensation Committee meeting in 2020 when the Committee reviews the performance-based metrics and determines if they were met or not with the remaining shares vesting on a semi-annual basis over a period of thirty-six months commencing on June 15, 2020 if the Company meets certain stock performance objectives compared to the NASDAQ Healthcare Index. The actual number of performance based stock awards that vest may be 0%, 50% or 100% of the numbers reflected above, depending upon the Company's performance. Read SEC document |
| February 13, 2019 Filed Feb 16, 2019 00:49 UTC |
JOHNSTON DAN SEVP & Chief Legal & Admin
|
GrantStock Option (Right to Buy) · Derivative | 12,759 | $0.00 Strike: $78.91 | $0.00 |
DisclosureSEC source: 0001179110-19-002028 · edgar.xml · derivative · entry 4 JOHNSTON DAN S · CIK 0001271802 · EVP & Chief Legal & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,759 Underlying: Common Stock · 12,759 shares Expires 2028-02-06 F2 · shares: Shares shall vest ratably over 48 month period, with a year cliff. Read SEC document |
| February 13, 2019 Filed Feb 16, 2019 00:49 UTC |
JOHNSTON DAN SEVP & Chief Legal & Admin
|
GrantCommon Stock | 3,496 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002028 · edgar.xml · nonDerivative · entry 3 JOHNSTON DAN S · CIK 0001271802 · EVP & Chief Legal & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,101 F3 · shares: The Performance-based restricted stock unit awards vest as to 25% of the shares on the date of the Compensation Committee meeting in 2020 when the Committee reviews the performance-based metrics and determines if they were met or not with the remaining shares vesting on a semi-annual basis over a period of thirty-six months commencing on June 15, 2020 if the Company meets certain stock performance objectives compared to the NASDAQ Healthcare Index. The actual number of performance based stock awards that vest may be 0%, 50% or 100% of the numbers reflected above, depending upon the Company's performance. Read SEC document |
| February 13, 2019 Filed Feb 16, 2019 00:49 UTC |
JOHNSTON DAN SEVP & Chief Legal & Admin
|
GrantCommon Stock | 3,041 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002028 · edgar.xml · nonDerivative · entry 2 JOHNSTON DAN S · CIK 0001271802 · EVP & Chief Legal & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,605 F1 · shares: RSU: Restricted Stock Units shall vest semiannually on 6/15 and 12/15 for a period of 4 years. Read SEC document |
| February 13, 2019 Filed Feb 16, 2019 00:48 UTC |
Seidelmann Scott PeterEVP, Chief Commercial Officer
|
GrantStock Options NQ (Right to Buy) · Derivative | 25,518 | $0.00 Strike: $78.91 | $0.00 |
DisclosureSEC source: 0001179110-19-002026 · edgar.xml · derivative · entry 4 Seidelmann Scott Peter · CIK 0001736895 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,518 Underlying: Common Stock · 25,518 shares Expires 2029-02-12 F2 · shares: NQ Options shall vest ratably over 48 month period, with a year cliff. Read SEC document |
| February 13, 2019 Filed Feb 16, 2019 00:48 UTC |
Seidelmann Scott PeterEVP, Chief Commercial Officer
|
GrantCommon Stock | 6,082 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002026 · edgar.xml · nonDerivative · entry 3 Seidelmann Scott Peter · CIK 0001736895 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,929 F1 · shares: Restricted Stock Units shall vest semiannually on 6/15 and 12/15 over a 4 year period. Read SEC document |
| February 13, 2019 Filed Feb 16, 2019 00:48 UTC |
Seidelmann Scott PeterEVP, Chief Commercial Officer
|
GrantCommon Stock | 6,991 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002026 · edgar.xml · nonDerivative · entry 2 Seidelmann Scott Peter · CIK 0001736895 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,847 F3 · shares: The Performance-based restricted stock unit awards vest as to 25% of the shares on the date of the Compensation Committee meeting in 2020 when the Committee reviews the performance-based metrics and determines if they were met or not with the remaining shares vesting on a semi-annual basis over a period of thirty-six months commencing on June 15, 2020 if the Company meets certain stock performance objectives compared to the NASDAQ Healthcare Index. The actual number of performance based stock awards that vest may be 0%, 50% or 100% of the numbers reflected above, depending upon the Company's performance. Read SEC document |
| February 13, 2019 Filed Feb 22, 2019 23:18 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 83,845 | $0.00 Strike: $78.91 | $0.00 |
DisclosureSEC source: 0001179110-19-002423 · edgar.xml · derivative · entry 6 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,845 Underlying: Common Stock · 83,845 shares Expires 2029-02-12 F3 · shares: Shares shall vest ratably over 48 month period, with a year cliff. Read SEC document |
| February 12, 2019 Filed Feb 12, 2019 22:36 UTC |
PETERSMEYER GARY SDirector
|
SaleCommon Stock | 750 | $78.87 | $59,154.60 |
DisclosureSEC source: 0001179110-19-001789 · edgar.xml · nonDerivative · entry 2 PETERSMEYER GARY S · CIK 0001206986 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,013 F1 · price: The price reported in Column 4 is the exact price of $78.8728. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 01, 2019 Filed Feb 1, 2019 22:55 UTC |
Taborga Jorge R.EVP, Global R & D
|
SaleCommon Stock | 132 | $64.09 | $8,459.64 |
DisclosureSEC source: 0001179110-19-001180 · edgar.xml · nonDerivative · entry 6 Taborga Jorge R. · CIK 0001571822 · EVP, Global R & D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,753 F5 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. F4 · price: The price reported in Column 4 is the average price of $64.0882. The sold price range between $64.02 to $64.11. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 01, 2019 Filed Feb 1, 2019 22:55 UTC |
Taborga Jorge R.EVP, Global R & D
|
SaleCommon Stock | 786 | $64.25 | $50,498.30 |
DisclosureSEC source: 0001179110-19-001180 · edgar.xml · nonDerivative · entry 5 Taborga Jorge R. · CIK 0001571822 · EVP, Global R & D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,885 F5 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. F3 · price: The price reported in Column 4 is the average price of $64.2472. The sold price range between $64.00 to $64.43. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 01, 2019 Filed Feb 1, 2019 22:55 UTC |
Taborga Jorge R.EVP, Global R & D
|
SaleCommon Stock | 645 | $64.24 | $41,435.19 |
DisclosureSEC source: 0001179110-19-001180 · edgar.xml · nonDerivative · entry 4 Taborga Jorge R. · CIK 0001571822 · EVP, Global R & D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,671 F5 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. F2 · price: The price reported in Column 4 is the average price of $64.2406. The sold price range between $64.09 to $64.43. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 01, 2019 Filed Feb 1, 2019 22:55 UTC |
Taborga Jorge R.EVP, Global R & D
|
SaleCommon Stock | 683 | $64.25 | $43,880.63 |
DisclosureSEC source: 0001179110-19-001180 · edgar.xml · nonDerivative · entry 3 Taborga Jorge R. · CIK 0001571822 · EVP, Global R & D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,316 F5 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. F1 · price: The price reported in Column 4 is the average price of $64.2469. The sold price range between $64.15 to $64.39. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 01, 2019 Filed Feb 1, 2019 22:55 UTC |
Taborga Jorge R.EVP, Global R & D
|
SaleCommon Stock | 263 | $64.50 | $16,963.50 |
DisclosureSEC source: 0001179110-19-001180 · edgar.xml · nonDerivative · entry 2 Taborga Jorge R. · CIK 0001571822 · EVP, Global R & D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,999 F5 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. Read SEC document |
| January 14, 2019 Filed Jan 14, 2019 22:35 UTC |
JOHNSTON DAN SEVP & Chief Legal & Admin
|
Exercise / conversionStock Options NQ (right to Buy) · Derivative | 5,209 | $0.00 Strike: $27.70 | $0.00 |
DisclosureSEC source: 0001179110-19-000715 · edgar.xml · derivative · entry 6 JOHNSTON DAN S · CIK 0001271802 · EVP & Chief Legal & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,209 Underlying: Common Stock · 5,209 shares Expires 2026-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. Read SEC document |
| January 14, 2019 Filed Jan 14, 2019 22:35 UTC |
JOHNSTON DAN SEVP & Chief Legal & Admin
|
Exercise / conversionStock Options NQ (right to Buy) · Derivative | 1,041 | $0.00 Strike: $34.02 | $0.00 |
DisclosureSEC source: 0001179110-19-000715 · edgar.xml · derivative · entry 5 JOHNSTON DAN S · CIK 0001271802 · EVP & Chief Legal & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,041 Underlying: Common Stock · 1,041 shares Expires 2025-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. Read SEC document |
| January 14, 2019 Filed Jan 14, 2019 22:35 UTC |
JOHNSTON DAN SEVP & Chief Legal & Admin
|
SaleCommon Stock | 2,652 | $64.21 | $170,278.29 |
DisclosureSEC source: 0001179110-19-000715 · edgar.xml · nonDerivative · entry 4 JOHNSTON DAN S · CIK 0001271802 · EVP & Chief Legal & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,564 F3 · price: The price reported in Column 4 is the average price of $64.2075. The sold price range was between $63.58 to $64.52. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 14, 2019 Filed Jan 14, 2019 22:35 UTC |
JOHNSTON DAN SEVP & Chief Legal & Admin
|
SaleCommon Stock | 6,250 | $64.14 | $400,891.25 |
DisclosureSEC source: 0001179110-19-000715 · edgar.xml · nonDerivative · entry 3 JOHNSTON DAN S · CIK 0001271802 · EVP & Chief Legal & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,216 F1 · price: The price reported in Column 4 is the average price of $64.1426. The sold price range was between $63.58 to $64.52. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 14, 2019 Filed Jan 14, 2019 22:35 UTC |
JOHNSTON DAN SEVP & Chief Legal & Admin
|
Exercise / conversionCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-000715 · edgar.xml · nonDerivative · entry 2 JOHNSTON DAN S · CIK 0001271802 · EVP & Chief Legal & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,466 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. Read SEC document |
| December 19, 2018 Filed Dec 19, 2018 23:53 UTC |
Ngo Nhat HEVP, Marketing, S & B D
|
SaleCommon Stock | 316 | $63.77 | $20,151.32 |
DisclosureSEC source: 0001179110-18-014157 · edgar.xml · nonDerivative · entry 3 Ngo Nhat H · CIK 0001305020 · EVP, Marketing, S & B D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,032 F3 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. F2 · price: The price reported in Column 4 is the average price of $63.77. The shares sold between $63.73 to 63.80. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 19, 2018 Filed Dec 19, 2018 23:53 UTC |
Ngo Nhat HEVP, Marketing, S & B D
|
SaleCommon Stock | 3,666 | $63.27 | $231,947.82 |
DisclosureSEC source: 0001179110-18-014157 · edgar.xml · nonDerivative · entry 2 Ngo Nhat H · CIK 0001305020 · EVP, Marketing, S & B D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,348 F3 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. F1 · price: The price reported in Column 4 is the average price of $63.27. The shares sold between $62.67 to 63.67. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 18, 2018 Filed Dec 18, 2018 22:49 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
SaleCommon Stock | 4,028 | $64.35 | $259,201.80 |
DisclosureSEC source: 0001179110-18-014083 · edgar.xml · nonDerivative · entry 5 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,543 F4 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. F3 · price: The price reported in Column 4 is the average price of $64.35. The shares sold between $64.00 to $64.70. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 18, 2018 Filed Dec 18, 2018 22:49 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
SaleCommon Stock | 5,454 | $63.55 | $346,601.70 |
DisclosureSEC source: 0001179110-18-014083 · edgar.xml · nonDerivative · entry 4 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,571 F4 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. F5 · price: The price reported in Column 4 is the average price of $63.55. The shares sold between $63.11 to $63.99. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 18, 2018 Filed Dec 18, 2018 22:49 UTC |
Kuipers Peter J.Executive V P& CFO
|
SaleCommon Stock | 2,429 | $64.18 | $155,898.32 |
DisclosureSEC source: 0001179110-18-014082 · edgar.xml · nonDerivative · entry 2 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,385 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. F1 · price: The price reported in Column 4 is the average price of $64.1821. The shares sold between $63.65 to $64.69. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2018 Filed Dec 17, 2018 22:47 UTC |
Kuipers Peter J.Executive V P& CFO
|
Tax withholdingCommon Stock | 2,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-013984 · edgar.xml · nonDerivative · entry 3 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,814 Read SEC document |
| December 15, 2018 Filed Dec 17, 2018 22:47 UTC |
Kuipers Peter J.Executive V P& CFO
|
Tax withholdingCommon Stock | 1,311 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-013984 · edgar.xml · nonDerivative · entry 2 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,231 F1 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| December 15, 2018 Filed Dec 17, 2018 22:47 UTC |
SPEARS JOSEPH BRIANChief Accounting Officer & VP
|
Tax withholdingCommon Stock | 563 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-013983 · edgar.xml · nonDerivative · entry 2 SPEARS JOSEPH BRIAN · CIK 0001729964 · Chief Accounting Officer & VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,121 F1 · price: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| December 15, 2018 Filed Dec 17, 2018 22:47 UTC |
JOHNSTON DAN SEVP & Chief Legal & Admin
|
Tax withholdingCommon Stock | 995 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-013981 · edgar.xml · nonDerivative · entry 3 JOHNSTON DAN S · CIK 0001271802 · EVP & Chief Legal & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,216 F1 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| December 15, 2018 Filed Dec 17, 2018 22:47 UTC |
JOHNSTON DAN SEVP & Chief Legal & Admin
|
Tax withholdingCommon Stock | 1,785 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-013981 · edgar.xml · nonDerivative · entry 2 JOHNSTON DAN S · CIK 0001271802 · EVP & Chief Legal & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,211 F1 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| December 15, 2018 Filed Dec 17, 2018 22:46 UTC |
Ngo Nhat HEVP, Marketing, S & B D
|
Tax withholdingCommon Stock | 930 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-013980 · edgar.xml · nonDerivative · entry 3 Ngo Nhat H · CIK 0001305020 · EVP, Marketing, S & B D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,014 F1 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| December 15, 2018 Filed Dec 17, 2018 22:46 UTC |
Ngo Nhat HEVP, Marketing, S & B D
|
Tax withholdingCommon Stock | 1,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-013980 · edgar.xml · nonDerivative · entry 2 Ngo Nhat H · CIK 0001305020 · EVP, Marketing, S & B D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,944 F1 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| December 15, 2018 Filed Dec 17, 2018 22:46 UTC |
Taborga Jorge R.EVP, Global R & D
|
Tax withholdingCommon Stock | 899 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-013979 · edgar.xml · nonDerivative · entry 3 Taborga Jorge R. · CIK 0001571822 · EVP, Global R & D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,262 F1 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| December 15, 2018 Filed Dec 17, 2018 22:46 UTC |
Taborga Jorge R.EVP, Global R & D
|
Tax withholdingCommon Stock | 1,559 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-013979 · edgar.xml · nonDerivative · entry 2 Taborga Jorge R. · CIK 0001571822 · EVP, Global R & D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,161 F1 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| December 15, 2018 Filed Dec 17, 2018 22:46 UTC |
Seidelmann Scott PeterEVP, Chief Commercial Officer
|
Tax withholdingCommon Stock | 375 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-013978 · edgar.xml · nonDerivative · entry 2 Seidelmann Scott Peter · CIK 0001736895 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,856 F1 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| December 15, 2018 Filed Dec 17, 2018 22:45 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
Tax withholdingCommon Stock | 2,864 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-013977 · edgar.xml · nonDerivative · entry 5 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,025 F3 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| December 15, 2018 Filed Dec 17, 2018 22:45 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
Tax withholdingCommon Stock | 8,376 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-013977 · edgar.xml · nonDerivative · entry 4 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,889 F3 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| December 15, 2018 Filed Dec 17, 2018 22:45 UTC |
Seim Robin GenePresident, Global A & M A
|
Tax withholdingCommon Stock | 2,137 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-013976 · edgar.xml · nonDerivative · entry 3 Seim Robin Gene · CIK 0001351911 · President, Global A & M A 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,747 F1 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| December 15, 2018 Filed Dec 17, 2018 22:45 UTC |
Seim Robin GenePresident, Global A & M A
|
Tax withholdingCommon Stock | 2,136 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-013976 · edgar.xml · nonDerivative · entry 2 Seim Robin Gene · CIK 0001351911 · President, Global A & M A 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,884 F1 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| December 10, 2018 Filed Dec 10, 2018 23:38 UTC |
Kuipers Peter J.Executive V P& CFO
|
Exercise / conversionStock Options NQ (Right to Buy) · Derivative | 1,884 | $0.00 Strike: $36.70 | $0.00 |
DisclosureSEC source: 0001179110-18-013647 · edgar.xml · derivative · entry 10 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,884 Underlying: Common Stock · 1,884 shares Expires 2027-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 10, 2018 23:38 UTC |
Kuipers Peter J.Executive V P& CFO
|
Exercise / conversionStock Options NQ (Right to Buy) · Derivative | 261 | $0.00 Strike: $36.70 | $0.00 |
DisclosureSEC source: 0001179110-18-013647 · edgar.xml · derivative · entry 9 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261 Underlying: Common Stock · 261 shares Expires 2027-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 10, 2018 23:38 UTC |
Kuipers Peter J.Executive V P& CFO
|
Exercise / conversionStock Options NQ (Right to Buy) · Derivative | 1,086 | $0.00 Strike: $27.70 | $0.00 |
DisclosureSEC source: 0001179110-18-013647 · edgar.xml · derivative · entry 8 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,086 Underlying: Common Stock · 1,086 shares Expires 2027-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 10, 2018 23:38 UTC |
Kuipers Peter J.Executive V P& CFO
|
Exercise / conversionStock Options NQ (Right to Buy) · Derivative | 2,343 | $0.00 Strike: $32.78 | $0.00 |
DisclosureSEC source: 0001179110-18-013647 · edgar.xml · derivative · entry 7 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,373 Underlying: Common Stock · 2,343 shares Expires 2025-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 10, 2018 23:38 UTC |
Kuipers Peter J.Executive V P& CFO
|
SaleCommon Stock | 1,884 | $70.12 | $132,113.05 |
DisclosureSEC source: 0001179110-18-013647 · edgar.xml · nonDerivative · entry 6 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,542 F5 · price: The price reported in Column 4 is the average price of $70.1237. The sold price range was between $69.20 to $71.43. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 10, 2018 Filed Dec 10, 2018 23:38 UTC |
Kuipers Peter J.Executive V P& CFO
|
SaleCommon Stock | 261 | $69.78 | $18,212.58 |
DisclosureSEC source: 0001179110-18-013647 · edgar.xml · nonDerivative · entry 5 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,426 F4 · price: The price reported in Column 4 is the exact price of $69.78. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 10, 2018 Filed Dec 10, 2018 23:38 UTC |
Kuipers Peter J.Executive V P& CFO
|
SaleCommon Stock | 1,086 | $70.13 | $76,163.13 |
DisclosureSEC source: 0001179110-18-013647 · edgar.xml · nonDerivative · entry 4 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,687 F3 · price: The price reported in Column 4 is the average price of $70.1318. The sold price range was between $69.20 to $71.39. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 10, 2018 Filed Dec 10, 2018 23:38 UTC |
Kuipers Peter J.Executive V P& CFO
|
SaleCommon Stock | 2,343 | $70.13 | $164,310.84 |
DisclosureSEC source: 0001179110-18-013647 · edgar.xml · nonDerivative · entry 3 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,773 F2 · price: The price reported in Column 4 is the average price of $70.1284. The shares sold between $69.20 to $71.39. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.